Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 106Carcinoma, Non-Small-Cell Lung 34Carcinoma, Renal Cell 23Prostatic Neoplasms 17Neoplasms 15Brain Neoplasms 15Neoplasm Metastasis 14Lung Neoplasms 12Breast Neoplasms 11Uveal Melanoma 10Pancreatic Neoplasms 10Sarcoma 9Small Cell Lung Carcinoma 7Urinary Bladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Kidney Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Skin Neoplasms 5Ovarian Neoplasms 5Histiocytoma, Malignant Fibrous 5Colorectal Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Mesothelioma 4Glioblastoma 4Colonic Neoplasms 4

Interventions

sonidegib 3HhAntag691 3tazarotene 2IPI-926 2Drug Evaluation 2merphos 1gusacitinib 1Vincristine 1Nivolumab 1NVP-BKM120 1Methotrexate 1Mental Status and Dementia Tests 1Ipilimumab 1Etoposide 1Cyclophosphamide 1Carboplatin 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Basal Cell Nevus Syndrome × Ipilimumab × Clear all
NCT03767439 2019-12-18

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Columbia University

Phase 2 Withdrawn
Dermatologic

Basal Cell Nevus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡